152 related articles for article (PubMed ID: 12648518)
1. Non-genomic effects of progestins--inhibition of cell growth and increased intracellular levels of cyclic nucleotides.
Sager G; Ørbo A; Jaeger R; Engström C
J Steroid Biochem Mol Biol; 2003 Jan; 84(1):1-8. PubMed ID: 12648518
[TBL] [Abstract][Full Text] [Related]
2. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus.
Chwalisz K; Stöckemann K; Fritzemeier KH; Fuhrmann U
Hum Reprod Update; 1998; 4(5):570-83. PubMed ID: 10027611
[TBL] [Abstract][Full Text] [Related]
3. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
[TBL] [Abstract][Full Text] [Related]
4. Induction of the angiogenic factor VEGF in the uterus by the antiprogestin onapristone.
Hyder SM; Chiappetta C; Stancel GM
Cancer Lett; 2000 Aug; 156(1):101-7. PubMed ID: 10840165
[TBL] [Abstract][Full Text] [Related]
5. Androgen-like and anti-androgen-like effects of antiprogestins in human mammary cancer cells.
Hackenberg R; Hannig K; Beck S; Schmidt-Rhode P; Scholz A; Schulz KD
Eur J Cancer; 1996 Apr; 32A(4):696-701. PubMed ID: 8695275
[TBL] [Abstract][Full Text] [Related]
6. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP.
Sartorius CA; Groshong SD; Miller LA; Powell RL; Tung L; Takimoto GS; Horwitz KB
Cancer Res; 1994 Jul; 54(14):3868-77. PubMed ID: 8033109
[TBL] [Abstract][Full Text] [Related]
7. The relationship between affinity of progestins and antiprogestins for the progesterone receptor in breast cancer cells (ZR-PR-LT) and ability to down-regulate the receptor: evidence for heterospecific receptor modulation via the glucocorticoid receptor.
van den Berg HW; Lynch M; Martin JH
Eur J Cancer; 1993; 29A(12):1771-5. PubMed ID: 8398308
[TBL] [Abstract][Full Text] [Related]
8. Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells.
Classen S; Possinger K; Pelka-Fleischer R; Wilmanns W
J Steroid Biochem Mol Biol; 1993 Apr; 45(4):315-9. PubMed ID: 8499339
[TBL] [Abstract][Full Text] [Related]
9. Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation.
Cameron ST; Critchley HO; Buckley CH; Kelly RW; Baird DT
Fertil Steril; 1997 Jun; 67(6):1046-53. PubMed ID: 9176442
[TBL] [Abstract][Full Text] [Related]
10. Modulatory actions of the new antiprogestins ZK 98.299 and ZK 98.734 and of RU 486 on luteinizing hormone secretion and progesterone effects in pituitary gonadotrophs.
Ortmann O; Hansemann K; Knuppen R; Emons G
J Steroid Biochem; 1990 Aug; 36(5):431-7. PubMed ID: 2214762
[TBL] [Abstract][Full Text] [Related]
11. Effects of GnRH analogues, 'add-back' steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression.
Chegini N; Ma C; Tang XM; Williams RS
Mol Hum Reprod; 2002 Dec; 8(12):1071-8. PubMed ID: 12468639
[TBL] [Abstract][Full Text] [Related]
12. Antiprogestins suppress basal and activin-stimulated follicle-stimulating hormone secretion in an estrogen-dependent manner.
Szabo M; Kilen SM; Saberi S; Ringstrom SJ; Schwartz NB
Endocrinology; 1998 May; 139(5):2223-8. PubMed ID: 9564826
[TBL] [Abstract][Full Text] [Related]
13. Non-competitive anti-oestrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of post-receptor proliferative mechanisms.
Neulen J; Williams RF; Breckwoldt M; Chwalisz K; Baulieu EE; Hodgen GD
Hum Reprod; 1996 Jul; 11(7):1533-7. PubMed ID: 8671500
[TBL] [Abstract][Full Text] [Related]
14. Molecular properties and preclinical pharmacology of JNJ-1250132, a steroidal progesterone receptor modulator that inhibits binding of the receptor to DNA in vitro.
Allan GF; Palmer E; Musto A; Lai MT; Clancy J; Palmer S
Steroids; 2006 Jul; 71(7):578-84. PubMed ID: 16597452
[TBL] [Abstract][Full Text] [Related]
15. Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats.
Stoeckemann K; Hegele-Hartung C; Chwalisz K
Hum Reprod; 1995 Dec; 10(12):3264-71. PubMed ID: 8822456
[TBL] [Abstract][Full Text] [Related]
16. [The molecular mechanisms of the action of antiprogestins].
Kareva EN; Solov'eva EV; Kirpichnikova NV; Tumanov AV
Eksp Klin Farmakol; 1999; 62(4):72-6. PubMed ID: 10513344
[No Abstract] [Full Text] [Related]
17. Antiprogestins and iatrogenic glucocorticoid resistance.
Koper JW; Molijn GJ; van Uffelen CJ; Stigter E; Lamberts SW
Life Sci; 1997; 60(9):617-24. PubMed ID: 9048964
[TBL] [Abstract][Full Text] [Related]
18. The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death.
Michna H; Schneider MR; Nishino Y; el Etreby MF
J Steroid Biochem; 1989; 34(1-6):447-53. PubMed ID: 2626038
[TBL] [Abstract][Full Text] [Related]
19. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914.
Attardi BJ; Burgenson J; Hild SA; Reel JR; Blye RP
Mol Cell Endocrinol; 2002 Feb; 188(1-2):111-23. PubMed ID: 11911951
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers.
Borras M; Lacroix M; Legros N; Leclercq G
Cancer Lett; 1997 Nov; 120(1):23-30. PubMed ID: 9570382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
